AEGiS-14IAC: Prevalence of mutations associated with antiretroviral drug resistance among newly diagnosed, drug-naïve men and women with HIV in ten U.S. cities, 1997-2000.

14th International AIDS Conference

Barcelona, Spain - July 7-12, 2002

Prevalence of mutations associated with antiretroviral drug resistance among newly diagnosed, drug-naïve men and women with HIV in ten U.S. cities, 1997-2000.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. TuOrC1190)

Bennett DE, Zaidi I, Heneine W, Woods T, Garcia-Lerma G, Weinstock H
Centers for Disease Control and Prevention, Atlanta, GA 30333, United States

BACKGROUND: Studies report that resistance to antiretroviral drugs is high in some areas among individuals newly diagnosed with HIV. Most US studies are small with limited demographic and risk factor variation.

METHODS: We prospectively evaluated the prevalence of mutations associated with antiretroviral drug resistance (MAR) among newly diagnosed untreated persons with HIV (not AIDS) sequentially enrolled in 10 US cities 1997-2000. Plasma specimens were analyzed using conventional sequencing. MAR include mutations listed as conferring resistance in the 12/01 International AIDS Society guidelines. Information on men and women was analyzed separately for factors associated with MAR.

RESULTS: Of 1032 participants, 770 (75%) were male and 262 were female. MAR prevalence was 7.2%. 8.5% of men and 4.6% of women had MAR (OR=1.5; 95% CI 0.94-7.63). MAR proportions in subgroups of > 25 persons are below. [table: see text] In univariate analysis, white men were significantly more likely than Black or Hispanic men to have MAR; MSM (men who have sex with men) and male drug injectors were significantly more likely to have MAR than men infected through sex with women (p<.02 for all associations). Using logistic regression, independent associations with MAR in men were seen for white race (OR=1.8;95% CI=1.1-3.1) and MSM (OR=2.2, 95% CI=1.1-4.2). Univariate and multivariate analyses showed no significant differences associated with MAR in female subgroups.

CONCLUSIONS: Overall MAR prevalence is lower in our sample than in some US studies in which white MSM predominate. Reported prevalences partly reflect the demographic and risk factor composition of the sample. For each subgroup, MAR prevalence reflects access to antiretroviral drugs, adherence, and other factors in transmitting partner groups.

Keywords: AEGIS, Prevalence, HIV, HIV Infections, HIV Seropositivity, Acquired Immunodeficiency Syndrome, United States, Risk Factors, Anti-HIV Agents, Drug Resistance, Drug Resistance, Viral, Cities, HIV Seroprevalence, Human, Female, Male, Epidemiology

020707
TuOrC1190